Product Code: GDHC1049FPR
GlobalData has released its pharma report, "Dry Eye Syndrome - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Dry Eye Syndrome Market. The report identifies and analyses the key companies shaping and driving the global Dry Eye Syndrome market. The report provides insight into the competitive Dry Eye Syndrome landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.
Scope
- Investigation of current and future market competition for Dry Eye Syndrome
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Dry Eye Syndrome sector through market impact analysis, future market scenario and company analysis
Reasons to buy
- Gain a high level view of the trends shaping and driving Dry Eye Syndrome market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What's the next big thing in the global Dry Eye Syndrome market landscape? Identify, understand and capitalize
Table of Contents
1. Table of Contents
- 1.1. List of Tables
- 1.2. List of Figures
2. Introduction
3. Market Outlook
- 3.1. Global Markets
- 3.1.1. Forecast
- 3.1.2. Drivers and Barriers - Global Issues
4. Current and Future Players
- 4.1. Overview
- 4.2. Trends in Corporate Strategy
- 4.3. Company Profiles
- 4.3.1. Alcon
- 4.3.2. Allergan
- 4.3.3. Herantis
- 4.3.4. Mimetogen
- 4.3.5. Mitotech
- 4.3.6. Otsuka
- 4.3.7. RegeneRx
- 4.3.8. Santen
- 4.3.9. Shire
5. Appendix
- 5.1. Bibliography
- 5.2. Abbreviations
- 5.3. Methodology
- 5.4. Forecasting Methodology
- 5.4.1. Diagnosed DES Patients
- 5.4.2. Percent Drug-Treated Patients
- 5.4.3. Launch Dates
- 5.4.4. General Pricing Assumptions
- 5.4.5. Individual Drug Assumptions
- 5.4.6. Pricing of Pipeline Agents
- 5.5. Primary Research - KOLs Interviewed for this Report
- 5.6. Primary Research - High-prescriber Survey
- 5.7. About the Authors
- 5.7.1. Analyst
- 5.7.2. Therapy Area Director
- 5.7.3. Epidemiologist
- 5.7.4. Global Head of Healthcare
- 5.8. About GlobalData
- 5.9. Disclaimer
List of Tables
- Table 1: Global Sales Forecast ($m) for DES Therapies, 2014-2024
- Table 2: DES Market - Drivers and Barriers, 2014-2024
- Table 3: Key Companies in the Dry Eye Syndrome Market in the 9MM, 2014
- Table 4: Allergan's DES Portfolio Assessment, 2015
- Table 5: Herantis's DES Portfolio Assessment, 2015
- Table 6: Mimetogen's DES Portfolio Assessment, 2015
- Table 7: Mitotech's DES Portfolio Assessment, 2015
- Table 8: Otsuka's DES Portfolio Assessment, 2015
- Table 9: RegeneRx's DES Portfolio Assessment, 2015
- Table 10: Santen's DES Portfolio Assessment, 2015
- Table 11: Shire's DES Portfolio Assessment, 2015
- Table 12: Key Launch Dates
- Table 13: Surveyed High-prescribing Physicians, by Country
List of Figures
- Figure 1: Global Sales for DES Therapies by Region, 2014 and 2024
- Figure 2: Global Sales by Region for DES Therapies, 2014-2024
- Figure 3: Global Sales for DES by Drug, 2014 and 2024
- Figure 4: Global Sales by Drug for DES Therapies, 2014-2024
- Figure 5: Company Portfolio Gap Analysis in Dry Eye Syndrome, 2014-2024
